Can Repeat Biopsy be Deferred in Patients Diagnosed with ASAP and mHGPIN with Negative mpMRI

Nyemkuna M. Fortingo,Brandon C Wilson,Ryan W Fogg,Sarah C Krzastek,Baruch M Grob

DOI: https://doi.org/10.1016/j.jnma.2024.07.105

IF: 2.739

2024-08-30

Journal of the National Medical Association

Abstract:Introduction and Objectives Though current AUA guidelines recommend additional testing in patients diagnosed with ASAP and mHGPIN, incidence of clinically significant prostate cancer (CSPC) after additional testing modalities such as multiparametric MRI (mpMRI) remain unclear. This study's objective was to investigate whether mpMRI can obviate the need for repeat prostate biopsy in those diagnosed with ASAP or mHGPIN. Methods An institutional retrospective review was performed from 2014 to 2022 to identify those with a first-time diagnosis of either ASAP or mHGPIN and who obtained an mpMRI within 3 months of repeat biopsy. Rates of CSPC diagnosis were assessed relative to mpMRI findings. Results Of the 61 patients identified, 40 were diagnosed with ASAP, 6 with mHGPIN and 15 with both. MpMRI found PIRADS-3 or higher (≥P3) lesions in 25 patients and PIRADS-2 or lower (≤P2) lesions in 36 patients. The ≥P3 group had 10 of the 13 patients subsequently diagnosed with CSPC, with 70% of patients having had ASAP or ASAP with mHGPIN initially. All three patients with mHGPIN in the ≤P2 group had negative biopsies. 9% of patients initially with ASAP plus or minus mHGPIN and ≤P2 had CSPC. Conclusion Only 8.3% of patients had GG2 or higher disease in the setting of a ≤P2 lesion, while 40% had GG2 or higher disease in the setting of ≥P3 lesions. Findings suggest that repeat biopsy may be deferred in patients with initial diagnosis of mHGPIN or ASAP with a negative mpMRI.

medicine, general & internal